Association of bilateral pan-uveitis with the use of trametinib for Langerhans cell histiocytosis

In conclusion, MEK (mitogen-activated protein/extracellular signal-related kinase kinase) inhibitor trametinib treatment alone might be associated with ocular toxicity presenting as Vogt Koyanaki Harada syndrome-like pan-uveitis. Ocular symptoms and signs should be monitored carefully during MEK inhibitor therapy.PMID:36628254 | PMC:PMC9827292
Source: American Journal of Translational Research - Category: Research Authors: Source Type: research